Metadifluoromescaline

Metadifluoromescaline
Clinical data
Other namesMDFM; 3-(Difluoromethoxy)-4,5-dimethoxyphenylethylamine; 3,4-Dimethoxy-5-(difluoromethoxy)phenethylamine
Routes of
administration		Oral[1][2]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 2-[3-(difluoromethoxy)-4,5-dimethoxyphenyl]ethan-1-amine
Chemical and physical data
FormulaC11H15F2NO3
Molar mass247.242 g·mol−1
3D model (JSmol)
  • NCCc1cc(OC(F)F)c(c(c1)OC)OC
  • InChI=1S/C11H15F2NO3/c1-15-8-5-7(3-4-14)6-9(10(8)16-2)17-11(12)13/h5-6,11H,3-4,14H2,1-2H3
  • Key:MGKIHHYUCREKFM-UHFFFAOYSA-N

Metadifluoromescaline (MDFM), also known as 3-(difluoromethoxy)-4,5-dimethoxyphenylethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[3][1][2] It is a difluorinated derivative of mescaline.[3][1][2] It has a dose of 85 mg or more orally and a duration of approximately 8 hours.[1][2] The drug is described as being slightly more potent than mescaline.[3] However, it is said to produce some rather unpleasant effects at the highest assessed dose of 85 mg, including physical discomfort, listlessness in the days after taking the drug, and a practical absence of hallucinogenic effects at this dose.[3][1] MDFM is a partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[2][1][3] It was first described in the scientific literature by Daniel Trachsel in 2012.[1][3][2] Subsequently, its pharmacology was studied in greater detail in 2021.[2]

See also

References

  1. ^ a b c d e f g Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819. In comparison to mescaline (22), metadifluoromescaline (MDFM, 75: Ki = 2988nM) has shown a slight increased affinity at the [3H]ketanserin-labelled serotonin h5-HT2A receptor. With 75 (85 mg, ~8 h), an anecdotal report states some rather unpleasant effects.
  2. ^ a b c d e f g Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  3. ^ a b c d e f Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. pp. 716, 718–719, 723. ISBN 978-3-03788-700-4.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.